NextCure (NXTC) Current Deferred Revenue (2018 - 2022)

NextCure's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $102000.0 for Q3 2022.

• In Q3 2022, Current Deferred Revenue fell 48.48% year-over-year to $102000.0; the TTM figure through Sep 2022 stood at $102000.0 (down 48.48% YoY), while the FY2021 annual figure was $217000.0, up 66.92% from the prior year.
• Current Deferred Revenue for Q3 2022 stood at $102000.0, up from $100000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $217000.0 in Q4 2021, with the low at $3000.0 in Q1 2019.
• The 5-year median for Current Deferred Revenue is $142000.0 (2020), against an average of $137466.7.
• The sharpest annual moves came in 2020 and 2022: Current Deferred Revenue surged 5333.33% in 2020, then slumped 50.74% in 2022.
• NextCure's Current Deferred Revenue stood at $28000.0 in 2018, then jumped by 667.86% to $215000.0 in 2019, then plunged by 39.53% to $130000.0 in 2020, then jumped by 66.92% to $217000.0 in 2021, then tumbled by 53.0% to $102000.0 in 2022.
• Business Quant data shows NXTC's Current Deferred Revenue at $102000.0 in Q3 2022, $100000.0 in Q2 2022, and $212000.0 in Q1 2022.